PIRS vs. BLRX, BTAI, VTVT, KZR, CASI, EGRX, DRRX, LEXX, CLNN, and CARM
Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include BioLineRx (BLRX), BioXcel Therapeutics (BTAI), vTv Therapeutics (VTVT), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Eagle Pharmaceuticals (EGRX), DURECT (DRRX), Lexaria Bioscience (LEXX), Clene (CLNN), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical preparations" industry.
BioLineRx (NASDAQ:BLRX) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
Pieris Pharmaceuticals has higher revenue and earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioLineRx received 226 more outperform votes than Pieris Pharmaceuticals when rated by MarketBeat users. Likewise, 73.26% of users gave BioLineRx an outperform vote while only 61.37% of users gave Pieris Pharmaceuticals an outperform vote.
1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 8.9% of Pieris Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
BioLineRx has a net margin of 0.00% compared to BioLineRx's net margin of -39.71%. BioLineRx's return on equity of -57.57% beat Pieris Pharmaceuticals' return on equity.
In the previous week, BioLineRx had 4 more articles in the media than Pieris Pharmaceuticals. MarketBeat recorded 4 mentions for BioLineRx and 0 mentions for Pieris Pharmaceuticals. Pieris Pharmaceuticals' average media sentiment score of 0.52 beat BioLineRx's score of 0.00 indicating that BioLineRx is being referred to more favorably in the media.
BioLineRx presently has a consensus price target of $21.00, indicating a potential upside of 3,034.33%. Given Pieris Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe BioLineRx is more favorable than Pieris Pharmaceuticals.
BioLineRx has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.
Summary
BioLineRx beats Pieris Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Pieris Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pieris Pharmaceuticals Competitors List
Related Companies and Tools
